Possible to Reduce Treatment Burden in HER2-Positive Breast Cancer?
This video examines the idea of using clinical features (age, tumor size) to reduce treatment burden in patients with HER2-positive breast cancer.
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses the idea of using clinical features to reduce treatment burden in patients with HER2-positive breast cancer.
While biomarkers that could help clinicians more appropriately personalize treatments for patients with HER2-positive disease are still in development, trials using clinical features have already explored different ways to reduce treatment toxicity.
Tolaney discusses one such trial, the APT (Adjuvant Paclitaxel and Trastuzumab) trial, which examined a less toxic regimen for patients with small HER2-positive tumors: 12 weeks of weekly paclitaxel (80 mg/m2) plus weekly trastuzumab (2 mg/kg), followed by 9 months of trastuzumab (6 mg/kg) every 3 weeks.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
